Rabeprazole
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Systematic (IUPAC) name | |
|---|---|
| 2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole | |
| Identifiers | |
| CAS number | 117976-89-3 |
| ATC code | A02BC04 |
| PubChem | 5029 |
| DrugBank | APRD01212 |
| ChemSpider | 4853 |
| Chemical data | |
| Formula | C18H21N3O3S |
| Mol. mass | 359.444 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 52% |
| Metabolism | mostly non-enzymatic, partly hepatic (CYP2C19) |
| Half life | 1 - 1.5 hours |
| Excretion | 90% renal |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Oral |
 (what is this?) (verify) |
|
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex (pronounced "acifex", referring to pH) in the US, Pariet in Japan and Canada, & Rablet in India.
Contents |
[edit] Indications and usage
Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
- Gastric ulcer
- Peptic ulcer disease (PUD)
- Maintenance of healing of erosive or ulcerative GERD
- Healing of erosive and ulcerative GERD
- Healing of duodenal ulcers.
- Treatment of symptomatic GERD
- Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
- Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
[edit] Contraindications
- hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
- pregnancy: FDA Pregnancy Ratings: B
- lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.
[edit] Restriction of usage
- acute hepatic failure
- pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)
[edit] Side effects
Rabeprazole adverse reactions/side effects include[citation needed]:
- In clinical trials the most common side effect assessed as possibly or probably related to AcipHex was headache in 2.4% of patients vs 1.6% taking placebo.
- diarrhea
- vomiting
- nausea
- abdominal pains
- constipation
- meteorism
- dry mouth
- increased or decreased appetite
- asthenia
- headache
- anxiety
- sleeplessness
- vertigo
- thrombocytopenia
- granulocytopenia
- leukocytopenia
- skin eruption
- erythema
- myalgia
- arthralgia
- muscle or bone pain
[edit] Drug interactions
Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).
[edit] Overdosage
There is no available data on symptoms of rabeprazole overdose.
[edit] Formulations
Rabeprazole as Rablet (Lupin), AcipHex, Rabeloc, Pariet is supplied in:
- Tablet, enteric-coated; 10mg
- Tablet, enteric-coated; 20mg
[edit] References
- Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.
- Prakash A, Faulds D., Rabeprazole, Drugs. 1998 Feb;55(2):261-7; discussion 268.
[edit] External links
|
|||||||||||||||||
